Posted inBiotechnology
FDA details rationale for rejecting rare disease gene therapy from Regenxbio
The FDA has released the rejection letter explaining its recent refusal of Regenxbio’s gene therapy for the rare disease Hunter…
Posted inBiotechnology
Why early developability assessment is a strategic necessity in modern antibody discovery
Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by decades of advances in…
Posted inBiotechnology
Theravance halves headcount, ends all R&D work after phase 3 rare disease fail
Theravance Biopharma is set to lay off 50% of its workforce, end all R&D work and scrap a blood pressure…
Posted inBiotechnology
New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program
Two new cancer cases have prompted Kyowa Kirin to shutter all clinical studies of its investigational anti-OX40 monoclonal antibody designed…
Posted inBiotechnology
Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug
Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its…
Posted inBiotechnology
New Pharmacokinetic Model Enhances Lacosamide Precision Dosing
In the rapidly evolving landscape of epilepsy treatment, precision dosing has emerged as a critical frontier promising enhanced therapeutic outcomes…
Posted inBiotechnology
High-Zoom Microscope with 4DPSF Aberration Correction
In a groundbreaking advancement that promises to redefine optical imaging, a team of researchers led by Yu, DX., Jiang, Z.,…
Posted inBiotechnology
Unveiling Frailty and Osteosarcopenia in Older Men
In recent years, the intersection of frailty and osteosarcopenia in aging populations has garnered significant attention from geriatric researchers worldwide.…
Posted inBiotechnology
Biohaven reduces scope of R&D cutbacks as pipeline progresses
Biohaven is powering ahead with its bold ambition to sharply reduce R&D spending—even as analysts warn the company will need…
Posted inBiotechnology
PSA vs. STN-DBS: Connectivity in Parkinson’s Revealed
In a groundbreaking study set to reshape the landscape of Parkinson’s disease treatment, researchers have unveiled critical insights into how…